News & Events

HighTide Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

October 14, 2022

ROCKVILLE, MD and SHENZHEN, CHINA, October 14, 2022 HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the company's Chief Development Officer, Leigh MacConell, Ph.D., will present at the H.C. Wainwright 6th Annual NASH Investor Conference at 2:30pm EDT on October 17, 2022. 

The H.C. Wainwright conference will include presentations by key opinion leaders in the area of nonalcoholic fatty liver disease.

The conference is being held virtually and is accessible via

About HighTide Therapeutics

HighTide is a globally integrated clinical-stage biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity, currently in clinical development for the treatment of nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), and primary sclerosing cholangitis (PSC). HTD1801 has received Fast Track designation from the US FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project. For more information, please visit


Jeffrey Dao


Share on WeChat circle of friends ×
Open WeChat
Use Scan to share web pages with your friends.

We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2020 HighTide Therapeutics Inc.